The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Sapience Therapeutics Completes $22.5 Million Series A Financing
Jul. 12, 2016 10:53AM PST
Company NewsSCARSDALE, NY–(Marketwired – July 12, 2016) – Sapience Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics to address difficult to treat oncology indications, announced that it has raised $22.5 million in a Series A financing. Sapience issued shares of its common stock in the financing. The proceeds of the financing will fund the …
SCARSDALE, NY–(Marketwired – July 12, 2016) – Sapience Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics to address difficult to treat oncology indications, announced that it has raised $22.5 million in a Series A financing. Sapience issued shares of its common stock in the financing.
The proceeds of the financing will fund the development of Sapience’s lead drug candidate, ST-36, which selectively targets a protein that promotes the growth of many types of tumors, including an aggressive type of brain cancer called glioblastoma (GBM).
The financing was led by Eshelman Ventures, with additional participation from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. Columbia University, which licensed its intellectual property to Sapience, is also a shareholder in the company.
Dr. Barry Kappel, chief executive officer and founder of Sapience Therapeutics, stated, “We are pleased to have the financial support of Eshelman Ventures, as well as a team of highly experienced advisors and directors, to guide us in the development of this potentially transformative cancer drug. Having this level of support speaks to the promise of the compound we licensed from Columbia University and the significant need for therapeutics to address some of the most serious and deadly types of cancer, such as GBM.”
Maxim Merchant Capital Group, a division of the Maxim Group LLC, acted as exclusive placement agent for the financing.
About Sapience Therapeutics
Sapience Therapeutics, Inc., is a privately held, preclinical stage biotechnology company focused on developing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma (GBM), which is the most severe and deadly form of brain cancer. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
The proceeds of the financing will fund the development of Sapience’s lead drug candidate, ST-36, which selectively targets a protein that promotes the growth of many types of tumors, including an aggressive type of brain cancer called glioblastoma (GBM).
The financing was led by Eshelman Ventures, with additional participation from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. Columbia University, which licensed its intellectual property to Sapience, is also a shareholder in the company.
Dr. Barry Kappel, chief executive officer and founder of Sapience Therapeutics, stated, “We are pleased to have the financial support of Eshelman Ventures, as well as a team of highly experienced advisors and directors, to guide us in the development of this potentially transformative cancer drug. Having this level of support speaks to the promise of the compound we licensed from Columbia University and the significant need for therapeutics to address some of the most serious and deadly types of cancer, such as GBM.”
Maxim Merchant Capital Group, a division of the Maxim Group LLC, acted as exclusive placement agent for the financing.
About Sapience Therapeutics
Sapience Therapeutics, Inc., is a privately held, preclinical stage biotechnology company focused on developing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma (GBM), which is the most severe and deadly form of brain cancer. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Contacts
Sapience Therapeutics, Inc.:
Barry Kappel
President and Chief Executive Officer
info@sapiencetherapeutics.com
Sapience Therapeutics, Inc.:
Barry Kappel
President and Chief Executive Officer
info@sapiencetherapeutics.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.